

Primary care rebate schemes

Primary care rebate schemes (PCRS) are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the ICB on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme **does not** influence the inclusion of specific medicines in care pathways or formularies. Healthcare professionals will continue to base their prescribing decisions on individual assessments of their patients' clinical circumstances. The decision to initiate treatment or change a patient's treatment regime should always be based on up-to-date best clinical evidence or guidance, for example, from the National Institute for Health and Clinical Excellence ('NICE'), or other approved authoritative sources.

North Central London ICB has signed up for the following primary care rebate schemes:

Rebate (Brand)	Generic name (if applicable)	Therapeutic area	Start date	Company
Clenil® Modulite® Inhaler	Beclometasone dipropionate	Asthma / Respiratory	01 April 2020	Chiesi Limited
FreeStyle® Libre® 2 Sensor	N/A	Diabetes / Endocrinology	01 May 2023	Abbott Laboratories Limited
Fostair® NEXThaler®	Beclometasone dipropionate with formoterol fumarate dihydrate	Asthma / Respiratory	01 July 2021	Chiesi UK Limited
Fostair® pMDI	Beclometasone dipropionate with formoterol fumarate dihydrate	Asthma / Respiratory	01 September 2021	Chiesi UK Limited
Prostap®	Leuprorelin	Endocrinology / Oncology	01 April 2020	Takeda UK Limited
Sereflo®	Fluticasone with salmeterol	Asthma / Respiratory	01 April 2020	Cipla EU Limited

The NCL ICB policy governing primary care rebate schemes can be accessed [here](#).



**Embrace
Diversity**



Collaborative



Support



Deliver



Efficient



Transparent



Accountable